Altimmune shareholders approve doubling authorized shares to 400M, re-elect all directors

Altimmune, Inc.

Authorized common stock increased from 200M to 400M via certificate of amendment, approved by 63.7M for vs. 24.2M against.
All 9 director nominees elected; broker non-votes of 35.9M on each. Highest votes for Jerome Durso at 47.6M.
Ratification of Ernst & Young as auditor passed with 85.0M for, 1.8M against, 1.5M abstain.
Say-on-pay advisory vote passed with 39.9M for, 12.0M against, 0.5M abstain.
Amendment to 2019 ESPP approved to increase reserve from 403,500 to 1,108,827 shares.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Altimmune, Inc.: Amended certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares (effective 2026-04-16).

Change: charter amendment
Effective: 2026-04-16

Exact text from the filing

On April 16, 2026, Altimmune, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) by filing a Certificate of Amendment with the Secretary of State of Delaware. The Certificate of Amendment reflected an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.